Origami Therapeutics
origamitherapeutics.comDeveloping next-generation disease-modifying protein degraders and correctors
Health & Wellnessbiotechneurodegenerative-diseasesprotein-degradationdrug-discoverysmall-moleculestherapeuticspharmaceutical
About
Origami Therapeutics is a biopharmaceutical company developing small molecule protein degraders and correctors targeting neurodegenerative diseases such as Alzheimer's, Huntington's, Parkinson's, ALS, and Frontotemporal Dementia. Their proprietary ORICISION™ platform enables selective degradation of disease-causing proteins while sparing normal protein forms, leveraging the body's natural protein disposal system. The company aims to address previously 'undruggable' targets with orally administered, blood-brain barrier-penetrating small molecules.
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's lack disease-modifying treatments that can selectively eliminate pathogenic proteins.
For
biotech investors, researchers, and clinical partners in neurodegenerative disease
How it works
The ORICISION™ platform discovers small molecule protein degraders and correctors that tag disease-causing proteins for removal via the body's natural disposal system, while sparing healthy protein forms.
Business model
unknown
Status
launched
Company
Origami Therapeutics